User:Achavez0921/Dalotuzumab

This is the sandbox page where you will draft your initial Wikipedia contribution.

If you're starting a new article, you can develop it here until it's ready to go live.

If you're working on improvements to an existing article, copy only one section at a time of the article to this sandbox to work on, and be sure to use an edit summary linking to the article you copied from. Do not copy over the entire article. You can find additional instructions here.

Remember to save your work regularly using the "Publish page" button. (It just means 'save'; it will still be in the sandbox.) You can add bold formatting to your additions to differentiate them from existing content.

Bibliography sandbox

Dalotuzumab is an anti-IGF1 receptor (IGF1R) humanized monoclonal antibody designed for the potential treatment of various cancers.^[1] Common adverse effects include hyperglycemia, nausea, vomiting, and fatigue.^[2] Dalotuzumab was developed by Merck and Co., Inc.^[3]

Indications

Dalotuzumab is indicated to treat breast cancer, colorectal cancer, multiple myeloma, neuroendocrine tumors, non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors.^[1]

Adverse Effects

Adverse effects of Dalotuzumab:^[1]^[2]^[4]

Mechanism of Action

adaptor proteins, Src-homology collagen (Shc) and insulin receptor substrate (IRS), are phosphorylated and, in turn, trigger the activation of the Ras/Raf/MEK/Erk and phosphoinositide 3-kinase (PI3K)/Akt signaling pathways, respectively.^[3] These signaling pathways are involved in the regulation of cell survival and cell cycle progression.^[3]

Furthermore,

extracellular domains of IGF1R, effectively blocking ligand activation of the receptor and preventing downstream signaling.^[3] Moreover, the binding of Dalotuzumab to IGF1R, as seen with other anti-IGF1R antibodies, downregulates the expression of the receptors by prompting the internalization and degradation of IGF1R.^[3]

History

There are now more than 30 different anti-IGF1R candidate drugs involved in over 70 industry and academic-initiated clinical trials.^[6]

Dalotuzumab (MK-0646) was developed by Merck and Co., Inc. under license from French pharmaceutical company, Pierre Fabre.^[3] Dalotuzumab presently remains in clinical trials and has not been granted FDA approval.^[7]

References

^
PMID 20521225. {{cite journal}}: Check date values in: |date= (help
)

^
PMID 24033707. {{cite journal}}: Check date values in: |date= (help
)

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Dalotuzumab Overview - Creative Biolabs". www.creativebiolabs.net. Retrieved 2023-01-01.
PMID 21813338. {{cite journal}}: Check date values in: |date= (help
)

^
ISSN 2352-3042. {{cite journal}}: Check date values in: |date= (help
)

ISSN 0167-6997
.

^ "SEER*Rx Interactive Antineoplastic Drugs Database". SEER. Retrieved 2023-01-01.

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Achavez0921/Dalotuzumab&oldid=1132488944"

[:0-1] 
PMID 20521225. {{cite journal}}: Check date values in: |date= (help
)

[:1-2] 
PMID 24033707. {{cite journal}}: Check date values in: |date= (help
)

[:2-3] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Dalotuzumab Overview - Creative Biolabs". www.creativebiolabs.net. Retrieved 2023-01-01.

[4] PMID 21813338. {{cite journal}}: Check date values in: |date= (help
)

[:3-5] 
ISSN 2352-3042. {{cite journal}}: Check date values in: |date= (help
)

[6] ISSN 0167-6997
.

[7] "SEER*Rx Interactive Antineoplastic Drugs Database". SEER. Retrieved 2023-01-01.

[1]

[2]

[3]

[4]

[6]

[7]